GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Total Receivables

INBX (Inhibrx Biosciences) Total Receivables : $0.42 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Total Receivables?

Inhibrx Biosciences's Total Receivables for the quarter that ended in Dec. 2024 was $0.42 Mil.


Inhibrx Biosciences Total Receivables Historical Data

The historical data trend for Inhibrx Biosciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Total Receivables Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23 Dec24
Total Receivables
0.26 0.78 0.42

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Receivables Get a 7-Day Free Trial Premium Member Only 0.78 0.30 1.39 1.13 0.42

Inhibrx Biosciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Inhibrx Biosciences Total Receivables Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibrx Biosciences Business Description

Traded in Other Exchanges
N/A
Address
11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.